Abstract：
UNASSIGNED: To examine how change in benzodiazepine (BZD) use is linked to changes in depressive symptoms intensity, worry intensity, and sleep quality over 16 months.
UNASSIGNED: Data come from a larger randomised controlled trial (RCT) named the \'Programme d\'Aide du Succès au SEvrage (PASSE-60+)\' study (NCT02281175). Seventy-three participants age 60 years and older took part in a 4-month discontinuation programme and were assessed four times over 16 months. Change in BZD use was defined as the difference in reported mg/day between two assessments. Control variables were RCT discontinuation group; BZD use at T1; and either depressive symptoms, worry intensity, or sleep quality at T1. Hierarchical multiple regressions were used to analyse data.
UNASSIGNED: In the short term, right after the discontinuation programme, sleep quality worsened with lower BZD use. This link was no longer significant at the 3- and 12-month follow-up. In the long term, depressive symptoms lowered with lower BZD use. No change was found in worry intensity in relation to BZD use at all measurement times.
UNASSIGNED: Discontinuation may improve depressive symptoms. Our study also questions the long-term effectiveness of BZD use, since long-term discontinuation was not linked with change in worry intensity and sleep quality.
UNASSIGNED: Data come from a larger randomised controlled trial (RCT) named the \'Programme d\'Aide du Succès au SEvrage (PASSE-60+)\' study (NCT02281175). Seventy-three participants age 60 years and older took part in a 4-month discontinuation programme and were assessed four times over 16 months. Change in BZD use was defined as the difference in reported mg/day between two assessments. Control variables were RCT discontinuation group; BZD use at T1; and either depressive symptoms, worry intensity, or sleep quality at T1. Hierarchical multiple regressions were used to analyse data.
UNASSIGNED: In the short term, right after the discontinuation programme, sleep quality worsened with lower BZD use. This link was no longer significant at the 3- and 12-month follow-up. In the long term, depressive symptoms lowered with lower BZD use. No change was found in worry intensity in relation to BZD use at all measurement times.
UNASSIGNED: Discontinuation may improve depressive symptoms. Our study also questions the long-term effectiveness of BZD use, since long-term discontinuation was not linked with change in worry intensity and sleep quality.
摘要：
■为了检查苯二氮卓（BZD）使用的变化如何与抑郁症状强度的变化有关，担心强度，16个月以上的睡眠质量。
■数据来自一项更大的随机对照试验（RCT），名为“SucconèsSevrage计划（PASSE-60+）”研究（NCT02281175）。73名年龄在60岁及以上的参与者参加了为期4个月的中止计划，并在16个月内接受了四次评估。BZD使用的变化定义为两次评估之间报告的mg/天的差异。控制变量为RCT停药组；T1时使用BZD；以及抑郁症状，担心强度，或睡眠质量在T1。分层多元回归用于分析数据。
■在短期内，就在中止计划之后，睡眠质量随着BZD使用率的降低而恶化。在3个月和12个月的随访中，这种联系不再重要。从长远来看,抑郁症状降低BZD的使用。在所有测量时间，与BZD使用相关的担忧强度均未发现变化。
■停药可改善抑郁症状。我们的研究还质疑BZD使用的长期有效性，因为长期停药与忧虑强度和睡眠质量的变化无关。
■数据来自一项更大的随机对照试验（RCT），名为“SucconèsSevrage计划（PASSE-60+）”研究（NCT02281175）。73名年龄在60岁及以上的参与者参加了为期4个月的中止计划，并在16个月内接受了四次评估。BZD使用的变化定义为两次评估之间报告的mg/天的差异。控制变量为RCT停药组；T1时使用BZD；以及抑郁症状，担心强度，或睡眠质量在T1。分层多元回归用于分析数据。
■在短期内，就在中止计划之后，睡眠质量随着BZD使用率的降低而恶化。在3个月和12个月的随访中，这种联系不再重要。从长远来看,抑郁症状降低BZD的使用。在所有测量时间，与BZD使用相关的担忧强度均未发现变化。
■停药可改善抑郁症状。我们的研究还质疑BZD使用的长期有效性，因为长期停药与忧虑强度和睡眠质量的变化无关。
